Io Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.16M
Io Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to discover and develop therapeutic compounds. The company develops and commercializes retinoid and rexinoid compounds targeting nuclear receptors for cancer, neurodegenerative, and autoimmune diseases, enabling patients to improve anti-cancer responses to checkpoint inhibitors, and chimeric antigen receptor-modified immune cells.
Contact Information
Website
www.io-therapeutics.comCorporate Office
- 9450 Pinecroft Drive
- Unit 9497
- Spring, TX 77387
- United States
Corporate Office
- 9450 Pinecroft Drive
- Unit 9497
- Spring, TX 77387
- United States
Io Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 01-Mar-2023 | $4.16M | Completed | Clinical Trials - Phase 2 | ||
| 2. Grant | 01-Jan-2015 | Completed | Startup | |||
| 1. Seed Round | 02-Jan-2014 | $444K | $444K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Io Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Io Therapeutics Patents
Io Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11976021-B2 | Synthesis of tetrahydronaphthalenols and uses thereof | Active | 27-Jun-2022 | ||
| US-20240246900-A1 | Synthesis of tetrahydronaphthalenols and uses thereof | Pending | 27-Jun-2022 | ||
| US-20230416190-A1 | Synthesis of tetrahydronaphthalenols and uses thereof | Active | 27-Jun-2022 | ||
| AU-2023301379-A1 | Synthesis of tetrahydronaphthalenols and uses thereof | Pending | 27-Jun-2022 | ||
| US-20230295069-A1 | Rxr agonist salt form, polymorphs thereof, and uses thereof | Active | 15-Mar-2022 | C07C57/50 |
Io Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Io Therapeutics FAQs
-
When was Io Therapeutics founded?
Io Therapeutics was founded in 2011.
-
Where is Io Therapeutics headquartered?
Io Therapeutics is headquartered in Spring, TX.
-
What is the size of Io Therapeutics?
Io Therapeutics has 4 total employees.
-
What industry is Io Therapeutics in?
Io Therapeutics’s primary industry is Drug Discovery.
-
Is Io Therapeutics a private or public company?
Io Therapeutics is a Private company.
-
What is Io Therapeutics’s current revenue?
The current revenue for Io Therapeutics is .
-
How much funding has Io Therapeutics raised over time?
Io Therapeutics has raised $4.6M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
